Teladoc Health, Inc. (TDOC)

NYSEHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-23

$6.34+0.32%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Teladoc Health, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q3
Revenue	$569M–$609M	—
EBITDA	$62M–$74Mnon-GAAP	—
FY 2026 · Q4
Revenue	—	597.4M
EPS	—	-0.109
FY 2026 · Annual
Revenue	$2.36B–$2.45B	2.41B
EPS	—	-0.869
EBITDA	$271M–$303Mnon-GAAP	—
Free cash flow	$130M–$170M	—
FY 2027 · Annual
Revenue	—	2.38B
EPS	—	-0.621

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Reduce net loss per share to between $0.75 and $1.05 in 2026	Teladoc aims to cut its net loss per share to about $0.9 in 2026.	Under Pressure	net loss per share worse than -$1.05 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Net loss per share improved from ($0.72) in first half 2025 to ($0.57) in first half 2026. Management narrowed full year 2026 net loss per share guidance to ($1.00) - ($0.75) in Q2 from ($1.05) - ($0.75) in Q1. The trajectory shows progress toward reducing net loss per share consistent with management's guidance. Delivery assessment Oct 24, 2026
Hit Q2 2026 revenue between $597 million and $626 million	A supporting condition in Teladoc Health, Inc.'s published investment case. The stated target is revenue between $597M and $626M.	Intact	Q2 2026 revenue below $597 million	Revenue: $606.927M FY2026-Q2; GAAP. Published target: revenue between $597M and $626M. Target period is not explicitly aligned with this observation. Source published Jul 30, 2026606,927,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 7c4cad98-80e9-4a08-a8a6-f8088f628994. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve revenue of about $2.56 billion in 2026	A primary condition in Teladoc Health, Inc.'s published investment case. The stated target is revenue between $2.48B and $2.58B.	Broken	revenue falls below $2.48 billion in FY26	Revenue: $606.927M FY2026-Q2; GAAP. Published target: revenue between $2.48B and $2.58B. Target period is not explicitly aligned with this observation. Source published Jul 30, 2026606,927,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 7c4cad98-80e9-4a08-a8a6-f8088f628994. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.62

Unavailable → $-0.62 · observed estimates

FY2027 revenue$2.38B

$2.54B → $2.38B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$2,537,215,750	4 / 22
2026-07-25	Unavailable	$2,537,898,930	4 / 22
2026-07-26	Unavailable	$2,537,898,930	4 / 22
2026-07-27	Unavailable	$2,537,898,930	4 / 22
2026-07-28	Unavailable	$2,537,898,930	4 / 22
2026-07-29	$-0.64	$2,539,381,359	10 / 18
2026-07-30	$-0.63	$2,522,198,544	10 / 18
2026-07-31	Unavailable	$2,453,474,570	2 / 21
2026-08-01	$-0.63	$2,451,326,516	10 / 17
2026-08-02	Unavailable	$2,432,059,460	2 / 20
2026-08-03	$-0.62	$2,444,497,944	10 / 17
2026-08-04	$-0.62	$2,444,497,944	10 / 17
2026-08-05	Unavailable	$2,411,101,950	2 / 20
2026-08-06	Unavailable	$2,411,101,950	2 / 20
2026-08-08	$-0.62	$2,444,497,944	10 / 17
2026-08-09	Unavailable	$2,411,101,950	2 / 20
2026-08-10	$-0.62	$2,444,497,944	10 / 17
2026-08-12	$-0.62	$2,444,497,944	10 / 17
2026-08-13	$-0.62	$2,444,497,944	10 / 17
2026-08-14	$-0.62	$2,444,497,944	10 / 17
2026-08-15	$-0.62	$2,444,497,944	10 / 17
2026-08-16	$-0.62	$2,444,497,944	10 / 17
2026-08-17	$-0.62	$2,444,497,944	10 / 17
2026-08-18	$-0.62	$2,444,497,944	10 / 17
2026-08-19	$-0.62	$2,444,497,944	10 / 17
2026-08-20	$-0.61	$2,381,652,389	10 / 17
2026-08-21	$-0.62	$2,380,954,656	10 / 17
2026-08-22	$-0.62	$2,380,954,656	10 / 17
2026-08-23	$-0.62	$2,380,954,656	10 / 17
2026-08-24	$-0.62	$2,380,954,656	10 / 17
2026-08-25	$-0.62	$2,380,954,656	10 / 17
2026-08-26	$-0.62	$2,380,954,656	10 / 17
2026-08-27	$-0.62	$2,380,954,656	10 / 17
2026-08-28	$-0.62	$2,380,954,656	10 / 17
2026-08-29	$-0.62	$2,380,954,656	10 / 17
2026-08-30	$-0.62	$2,380,954,656	10 / 17
2026-08-31	$-0.62	$2,380,954,656	10 / 17
2026-09-01	$-0.62	$2,380,955,642	10 / 17
2026-09-02	$-0.62	$2,380,954,656	10 / 17
2026-09-03	$-0.62	$2,380,954,656	10 / 17
2026-09-04	$-0.62	$2,380,954,656	10 / 17
2026-09-05	$-0.62	$2,380,954,656	10 / 17
2026-09-06	$-0.62	$2,380,954,656	10 / 17
2026-09-07	$-0.62	$2,380,954,656	10 / 17
2026-09-08	$-0.62	$2,380,954,656	10 / 17
2026-09-09	$-0.62	$2,380,954,656	10 / 17
2026-09-10	$-0.62	$2,380,954,656	10 / 17
2026-09-11	$-0.62	$2,380,954,656	10 / 17
2026-09-12	$-0.62	$2,380,954,656	10 / 17
2026-09-13	$-0.62	$2,380,954,656	10 / 17
2026-09-14	$-0.62	$2,380,954,656	10 / 17
2026-09-15	$-0.62	$2,380,954,656	10 / 17
2026-09-16	$-0.62	$2,380,954,656	9 / 17
2026-09-17	$-0.62	$2,380,954,656	9 / 17
2026-09-18	$-0.62	$2,380,954,656	9 / 17
2026-09-19	$-0.62	$2,380,954,656	9 / 17
2026-09-20	$-0.62	$2,380,954,656	9 / 17
2026-09-21	$-0.62	$2,380,954,656	9 / 17
2026-09-22	$-0.62	$2,380,954,656	9 / 17
2026-09-23	$-0.62	$2,380,954,656	9 / 17
2026-09-24	$-0.62	$2,380,954,656	9 / 17
2026-09-25	$-0.62	$2,380,954,656	9 / 17
2026-09-26	$-0.62	$2,380,954,656	9 / 17
2026-09-27	$-0.62	$2,380,954,656	9 / 16
2026-09-28	$-0.62	$2,380,954,656	9 / 16
2026-09-29	$-0.63	$2,380,445,565	9 / 16
2026-09-30	$-0.63	$2,380,445,565	9 / 16
2026-10-01	$-0.63	$2,380,445,565	9 / 16
2026-10-02	$-0.63	$2,380,443,415	9 / 16
2026-10-03	$-0.63	$2,380,443,415	9 / 16
2026-10-04	$-0.63	$2,380,443,415	9 / 16
2026-10-05	$-0.63	$2,380,443,415	9 / 16
2026-10-06	$-0.63	$2,380,443,415	9 / 16
2026-10-07	$-0.63	$2,375,788,415	9 / 16
2026-10-08	$-0.63	$2,375,788,415	10 / 17
2026-10-09	$-0.63	$2,375,788,415	10 / 17
2026-10-10	$-0.63	$2,375,788,415	10 / 17
2026-10-11	$-0.63	$2,375,788,415	10 / 17
2026-10-12	$-0.63	$2,375,788,415	10 / 17
2026-10-13	$-0.63	$2,375,788,415	10 / 17
2026-10-14	$-0.63	$2,375,788,415	10 / 17
2026-10-15	$-0.63	$2,375,788,415	10 / 17
2026-10-16	$-0.63	$2,375,788,415	10 / 17
2026-10-17	$-0.63	$2,375,788,415	10 / 17
2026-10-18	$-0.63	$2,375,763,415	10 / 17
2026-10-19	$-0.63	$2,375,763,415	10 / 17
2026-10-20	$-0.62	$2,375,763,415	10 / 17
2026-10-21	$-0.62	$2,375,763,415	10 / 17
2026-10-22	$-0.62	$2,375,763,415	10 / 17
2026-10-23	$-0.62	$2,375,763,415	9 / 17
2026-10-24	$-0.62	$2,375,763,415	9 / 17

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	7	19
2026-06-01	7	19
2026-07-01	7	18
2026-08-01	6	18
2026-09-01	6	18
2026-10-01	6	17

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 17 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce net loss per share to between $0.75 and $1.05 in 2026Published status: Under Pressure
Hit Q2 2026 revenue between $597 million and $626 millionRevenue: $606.927M
Achieve revenue of about $2.56 billion in 2026Published status: Broken

Next proof point

Oct 28, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-52.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Teladoc Health, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a higher-risk recovery case, not a proven durable grower, because the company remains loss-making and recent financial performance trails its industry cohort. The long-term thesis is in a watch state: Integrated Care is making progress, but the wider business has not yet shown a clear growth trend.

What's priced into Teladoc Health, Inc.

TDOC is described as cheap versus peers, while the valuation model has low confidence and its expectations gap is negative. The evidence labels pricing as justified with low fragility, but does not specify exactly what future performance the market assumes.

What the fundamentals likely do

Near term, revenue is under pressure: first-half revenue fell 3% year over year, and management lowered its full-year 2026 revenue guidance. Loss per share improved in the first half, while Integrated Care revenue grew modestly and its adjusted EBITDA margin expanded; adjusted EBITDA means earnings before interest, taxes, depreciation, and amortization. A guidance cut remains a risk, although the latest quarter was reported as an earnings beat and the stated near-term miss risk is low.

What Teladoc Health, Inc. hinges on

Over the next few quarters, the thesis hinges on delivering the revised revenue guidance and continuing to narrow losses while Integrated Care growth and margin gains persist. A guidance cut or further weakening in jobs data would add pressure; continued earnings strength and higher guidance from healthcare peers could support the sector backdrop.